Published in Cancer Weekly, September 4th, 1995
Physicians may soon be able to tell which of their patients with prostate cancer need aggressive treatment.
Researchers at Detroit's Barbara Ann Karmanos Cancer Institute have isolated a potential marker for determining the aggressiveness of human prostate cancer. Their work, published in the August  issue of Urology, found that elevated levels of 12-LOX, an enzyme, may indicate poor prognosis.
"We found that tumors with high 12-LOX expression are likely to have high metastatic potential or are locally advanced tumors," said David...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.